The short version
6 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Jardiance
Empagliflozin · EMPAGLIFLOZIN 25 mg/1 · Tablet, Film Coated · Oral · Aphena Pharma Solutions - Tennessee, LLC
NDC 71610-0177-09 · 9000 TABLET, FILM COATED in 1 BOTTLE · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00597-0153-30) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$6.79per unit
middle half $6.79–$6.79 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
$4.08–$5.10
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
100%of plans cover it
tier 3 · prior auth 0% · step therapy 2% · qty limit 97%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for empagliflozin (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- Aphena Pharma Solutions - Tennessee, LLCUnited Statesrepack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,005.96 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA204629
- TE code
- —
- Approval date
- Aug 1, 2014
- Patents / exclusivity
- 51 patents, 5 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | PED | Dec 20, 2026 |
| exclusivity | PED | Dec 20, 2026 |
| exclusivity | I-922 | Sep 21, 2026 |
| exclusivity | NPP | Jun 20, 2026 |
| exclusivity | NPP | Jun 20, 2026 |
| patent | 9949998*PED | Dec 11, 2034 |
| patent | 9949998*PED | Dec 11, 2034 |
| patent | 9949997*PED | Nov 17, 2034 |
| patent | 9949997*PED | Nov 17, 2034 |
| patent | 10258637*PED | Oct 3, 2034 |
| patent | 12433906*PED | Oct 3, 2034 |
| patent | 11090323*PED | Oct 3, 2034 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Empagliflozin (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | EMPAGLIFLOZIN 25 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Aphena Pharma Solutions - Tennessee, LLC | EMPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aphena Pharma Solutions - Tennessee, LLC | EMPAGLIFLOZIN 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Boehringer Ingelheim Hellas Single Member S.a. | EMPAGLIFLOZIN 25 mg/25mg | Jul 15, 2026 | Sep 2, 2026 |
| Boehringer Ingelheim Hellas Single Member S.a. | EMPAGLIFLOZIN 10 mg/10mg | Jul 15, 2026 | Sep 2, 2026 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | EMPAGLIFLOZIN 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | EMPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Cardinal Health 107, LLC | EMPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Cardinal Health 107, LLC | EMPAGLIFLOZIN 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| A-S Medication Solutions | EMPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
| Redpharm Drug | EMPAGLIFLOZIN 25 mg/1 | Aug 28, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Jardiance — NDC 71610-0177-09," retrieved September 3, 2026, https://drugdashboards.com/drug/71610017709.
Free to cite with attribution — see how the data is put together.